Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Wenzel

Showing results (211-220 of 213) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 213 results.
European Urology|December 3, 2023
Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical OutcomesFederico Piramide, Filippo Turri, Daniele Amparore, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Minerva Urology and Nephrology|June 23, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 studyPasquale Rescigno, Tarek Taha, Maria J Fita, et al.
Pageof 22

Showing results (211-220 of 213) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 213 results.
European Urology|December 3, 2023
Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical OutcomesFederico Piramide, Filippo Turri, Daniele Amparore, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Minerva Urology and Nephrology|June 23, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 studyPasquale Rescigno, Tarek Taha, Maria J Fita, et al.
Pageof 22